Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and regulates iron metabolism. Additional data are needed …

Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …

Background Concerns regarding cardiovascular safety with current treatments for anemia in
patients with dialysis-dependent (DD)-CKD have encouraged the development of …

Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …

Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …

Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …

Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …

Introduction Erythropoiesis-stimulating agents, standard of care for anemia of end-stage
kidney disease, are associated with cardiovascular events. We evaluated the efficacy and …

Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …

Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
has demonstrated safety and efficacy versus placebo in phase III trials in patients with …